Revance Therapeutics Q3 EPS $(0.37) Beats $(0.38) Estimate, Sales $59.88M Miss $68.20M Estimate
Revance Therapeutics Q3 EPS $(0.37) Beats $(0.38) Estimate, Sales $59.88M Miss $68.20M Estimate
revance therapeutics 第三季每股收益爲$(0.37)，超過$(0.38)的預期，銷售額爲5988萬美元，低於6820萬美元的預期
Revance Therapeutics (NASDAQ:RVNC) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.38) by 2.63 percent. This is a 77.3 percent increase over losses of $(1.63) per share from the same period last year. The company reported quarterly sales of $59.88 million which missed the analyst consensus estimate of $68.20 million by 12.20 percent. This is a 10.66 percent increase over sales of $54.11 million the same period last year.
revance therapeutics（納斯達克:RVNC）報告每股虧損0.37美元，超過了分析師預期的0.38美元，增幅爲2.63%。這比去年同期每股虧損1.63美元增長了77.3%。公司報告的季度銷售額爲5988萬美元，低於分析師預期的6820萬美元，下降了12.20%。這是與去年同期銷售額5411萬美元相比增長了10.66%。
資訊熱榜
更新時間